文献速递妇科生殖医学

早期子宫内膜样癌保留生育功能内分泌治疗的最佳时长

Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2021-04-17

该回顾性研究纳入2005—2018年接受保留生育功能治疗(FST)的122例疑似IA期1级子宫内膜癌患者,比较≤6个月与>6个月FST的肿瘤学结局。105例(86.1%)获完全缓解(CR),中位达CR时间10(3–42)个月;≤6个月与>6个月组总CR率无显著差异(88.9% vs 84.9%,P=0.436)。分段回归显示以首次FST后15个月为界,累计CR率变化显著不同(P=0.0015),进展率3.3%(4/122)。

要点

  • 6个月未达CR且无进展者可继续FST,不必立即手术。
  • ≤6个月与>6个月FST的总CR率无显著差异(P=0.436)。
  • 排除进展后,15个月可视为最佳FST时长 cutoff。

核心结论

  • 6个月FST未达CR且未显示进展者可继续FST。
  • 若排除疾病进展,15个月FST可视为最佳FST时长的cutoff。

研究设计与样本

  • 回顾性分析2005—2018年因疑似IA期1级子宫内膜癌接受FST的患者。
  • 比较≤6个月与>6个月FST两组的肿瘤学结局,并用分段回归估计累计CR率随FST时长的动态变化。

主要发现

  • 122例接受口服孕激素,其中108例(88.5%)同时使用左炔诺孕酮宫内缓释系统。
  • 105例(86.1%)达CR,中位达CR时间10(3–42)个月。
  • 6个月FST未达CR者中95.1%(78/82)继续进一步FST。
  • ≤6个月与>6个月FST组总CR率分别为88.9%(32/36)与84.9%(73/86),差异无统计学意义(P=0.436)。
  • 以首次FST后15个月为界的两分段累计CR率变化显著不同(P=0.0015,分段回归分析)。

关键数值与推荐

  • 6个月FST未达CR且无进展者可继续FST。
  • 排除疾病进展后,15个月FST可考虑为最佳FST时长cutoff。

临床怎么用

  • 对6个月未达CR但无进展的早期子宫内膜样癌患者可继续FST而非立即转手术。
  • FST期间应监测进展,进展首次检测于9–12个月期间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To analyze the oncologic outcomes of long-term fertility-sparing treatment (FST) in patients with early-stage endometrial cancer (EC) and to determine the optimal duration of FST that would not hamper survival outcomes. METHODS: Patients undergoing FST for presumed stage IA, grade 1 EC between 2005 and 2018 were retrospectively analyzed. Oncologic outcomes were compared between the group with ≤6 months of FST and the group with >6 months of FST. Segmented regression analysis was used to estimate the dynamic changes in cumulative complete response (CR) rates according to FST duration. RESULTS: A total of 122 patients received oral progestin, with concurrent levonorgestrel-releasing intrauterine device use in 108 (88.5%) and 105 (86.1%) achieved CR with a median time to achieve CR of 10 (3-42) months. Of the patients not achieving CR at 6 months of FST, 95.1% (78/82) continued further FST. The overall CR rate (88.9% [32/36] vs. 84.9% [73/86], P = 0.436] was not significantly different between the groups with ≤6 and > 6 months of FST. The changes in cumulative CR rates were significantly different between the two segments divided by 15 months from the initial FST (P = 0.0015, segmented regression analysis). The overall progressive disease (PD) rate was 3.3% (4/122), and PD was first detected during 9-12 months of FST. CONCLUSION: Patients not achieving CR and not showing PD at 6 months of FST could continue further FST. If disease progression is excluded, 15 months of FST can be considered as the cutoff for the optimal FST duration.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Shim SH, Chae SH, So KA, et al. Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer. Gynecol Oncol. 2021. PMID: 33875233. doi:10.1016/j.ygyno.2021.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。